PCSK9 and coronary artery disorder: Current lipid-lowering therapies involving statins, ezetimibe, and proprotein convertase subtilisin/kexin type-9 (PCSK-9) inhibitors have been established as standard therapies for coronary artery disease (CAD)14,15.